Big news today! insitro has appointed industry-leading scientist & drug hunter Philip Tagari as CSO. We’re very excited for Philip to partner with our founder & CEO Daphne Koller and our world-class team as we transform drug discovery & development. bwnews.pr/3gRAazO

Looking forward to tomorrow's panel discussion on #biotech #entrepreneurship & #intrapreneurship at the BioNJ Conference! I'm excited to spend the day with such an amazing group of women in STEM 🔬🧪🤩 tinyurl.com/55b7s8s9

BioAge is pleased to announce positive topline Phase 1b data showing that our apelin receptor agonist BGE-105 prevented muscle atrophy in healthy volunteers aged ≥65 years on bed rest. businesswire.com/news/home/2022… Keep reading to learn why we’re so excited about this. (🧵 1/6)

Thanks to BIOS and Chris Ghadban for hosting me and highlighting a16z Bio + Health on the podcast! Enjoyed chatting about topics ranging from career paths to biotech venture and DE&I in company building. 🎧Listen in!

Synthetic biology gives us the opportunity to reimagine how we build our world. But we need better tools. Congratulations to a16z portco Asimov on raising $200m to integrate synthetic biology + computer-aided design to engineer more advanced therapies. 💻 🧬 a16z Bio + Health

I chatted with Marc Andreessen 🇺🇸 about the implications of recent AI advances in healthcare. Watch the full video from @a16zbiohealth 's Bio Eats World. 👇 youtu.be/c7ScUDYSRYo

📽️Learning about a16z's investment philosophy in Bio + Health from Jorge Conde. We discuss software, digital health, and the critical importance of founders in early stage investing. Go Canes. #JPM23

Biotech needs a tech upgrade. We have astounding advances in science. Software needs to step up. As founders build better software for science, SaaS will modernize how drugs are discovered, developed + distributed. @jayrughani & I sketch it out: ✍️a16z a16z.com/2023/02/14/doi…

1/ So excited to be publicly sharing Memora Health's $30M strategic financing led by Chris Bischoff Hemant Taneja and General Catalyst along with several strategic partners including Northwell Health, @NorthShoreWeb, Steve Pagliuca, and others! memorahealth.com/news/memora-he…

How can you distribute your healthtech product more broadly? One way is by selling through channel partners.  Julie Yoo, @annie_m_collins, & I explore how in our next GTM piece by the a16z team: a16z.com/2023/05/02/cha…

I had such a wonderful time with my former colleagues at the Alnylam Pharmaceuticals #ALumNY event last night. So many amazing people who contributed to the journey and a lasting community. This is the leadership team that set the bar!!

How can #VBC grow in #Medicaid? How can we get real health outcome change vs “value veneers”? “Value-based arrangements need to extend beyond bonus payments for cost/quality targets and provide net NEW services for patients that are not possible under fee-for-service” care 👏🏼

We are thrilled to welcome Greg Verdine to the a16z Bio + Health team as a Venture Partner! Greg is a unique leader in both the academic + biotech worlds, a new drug modality pioneer, and a serial founder. 🎧 More below, and Greg's story in his own voice! a16z.com/2023/07/20/gre…

1/ Excited to see Jacob Borrajo Jacob Borrajo and Basem Al-Shayeb Basem Al-Shayeb, Ph.D. 🧬, co-founders of Amber Bio, unveil a bit of what they have been hard at work building! cc a16z Bio + Health businesswire.com/news/home/2023…

🚨 Today, we’re thrilled to share our study expanding the gene editing toolbox to enable virtually any kind of edit in gene transcripts at the order of thousands of bases. A thread 🧵👇(1/n) biorxiv.org/content/10.110…

How are healthcare leaders evaluating & deploying AI solutions today? We a16z interviewed many of the largest healthcare orgs to highlight how their eval criteria for AI solutions might inform how entrepreneurs bring their products to market.

We did it! FDA IND clearance of NTLA-2001! I’m so proud of our team. Congrats to all! A big thank you to our clinical trial participants and sites, as well as our investigators who are contributing to the advancement of our therapies. The future looks bright! #OneIntellia

🚀 NEWS: We’ve entered a research collaboration with AbbVie to leverage #ArtificialIntelligence and #MachineLearning to develop next-generation therapeutic antibodies in oncology and neuroscience. bighatbio.com/news/abbvie-an…

Recently, Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉, Barbara and Edward Netter Professor in Cancer Gene Therapy at the U of Penn, joined Jorge Conde and Ginger Liau on Raising Health to discuss how CAR T therapy is expanding beyond oncology to treat autoimmune diseases, like lupus. By targeting B cells with

I always love chatting with Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉 and learning from his experience as co-inventor of Kymriah and a shepherd of CAR T cell tx tech. this time, it happens to be recorded! check out Jorge Conde and my conversation with Bruce - a16z.com/podcast/the-hi…